4D Molecular Therapeutics Inc

NASDAQ:FDMT   3:59:54 PM EDT
24.31
-0.26 (-1.06%)
Products, Regulatory

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update

Published: 06/24/2021 11:45 GMT
4D Molecular Therapeutics Inc (FDMT) - 4d Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4d-110 for Choroideremia and 4d-125 for Xlrp, and Termination of Roche Collaboration and License Agreement.
4d Molecular Therapeutics Inc - 4dmt Will Regain Full-rights to 4d-110 As a Result of Roche's Termination of Collaboration and License Agreement.
4d Molecular Therapeutics Inc - 4d-110: Initial Clinical Safety Data at Both of Two Dose Levels in Phase 1 Clinical Trial Indicate That 4d-110 Was Well-tolerated.
4d Molecular - 4d-125: Initial Data at Both of Two Dose Levels in Phase 1 Portion of a Phase 1/2 Clinical Trial Indicate That 4d-125 Was Well-tolerated.